Y-box binding protein 1 pseudogene 8Genealiases: []
Q-omics provides the consensus-scored YBX1P8 profile across patient tissues and cancer cell-line models. YBX1P8 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, YBX1P8 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, YBX1P8 RNA expression shows 8,148 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight KIRC, LUSC, and LAML as cancer lineages where YBX1P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YBX1P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YBX1P8 survival associations across molecular data types. YBX1P8 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YBX1P8 RNA expression–survival associations across cancer types. High YBX1P8 expression shows unfavorable associations in KIRC, READ, ACC, THCA and CHOL, but favorable associations in CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for YBX1P8 RNA expression.
This table summarizes YBX1P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for YBX1P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YBX1P8 shows lower tumor expression in THCA and higher tumor expression in LUSC, STAD, LUAD and CHOL. The LUSC box plot shows higher YBX1P8 RNA expression in tumor versus normal tissue (log2 FC = +0.044, t-test p = .001).
This table shows molecular features associated with YBX1P8 in patient tissues and cancer cell lines. In patient samples, YBX1P8 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
